BOULDER, Colo.–(BUSINESS WIRE)—- $BDSX #patientsfirst–Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that the large multi-center observational registry study INSIGHT (Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects) (NCT03289780) has completed enrollment of 5,000 patients with non-small cell lung cancer (NSCLC). The study was designed to further validate the utility of the
Click here to view original post
News
Historic $40 Million Gift to CU Anschutz Dept. of Ophthalmology will Fuel Research and New Therapies
The University of Colorado Anschutz Medical Campus announced today that its Department of Ophthalmology received a historic $40 million gift to treat and potentially cure eye diseases like macular degeneration and glaucoma, increase focus on […]
News
New Denver-area vet clinics underscore a changing industry
New models of pet care, such as traveling clinics and vet ownership models, emerge as a solution to burnout. Click here to view original post
News
Children’s Hospital expands AI partnership with custom tech
Currently, the technology can predict how many patients will occupy the hospital up to three days in advance with 98% accuracy. Click here to view original post
